Abstract:Metabolism of cancer cells is different from normal cells and heterogeneous. To meet energetic and material needs for high-rate proliferation and tumorigenesis, cancer cells generally rely more heavily on vital exogenous nutrients (e.g. glucose, amino acids, and vitamins) than normal cells. Therefore, control of nutrient transport and metabolism in cancer cells is a novel anticancer strategy. Our previous studies have suggested that microRNA-1291-5p (miR-1291-5p) is downregulated in pancreatic cancer (PC) cells and acts a tumor suppressor. The current study aimed to develop a new approach to produce and employ fully-humanized recombinant miR-1291 agent to investigate its mechanistic actions in the regulation of PC cell metabolism and combination therapy with other metabolic modulators. We first cloned and achieved high-level heterogenous expression of humanized recombinant pre-miR-1291 in bacteria using human serine-tRNA (htRNASer) as a carrier. We then produced htRNASer/pre-miR-1291 (htRNASer/miR-1291) on large scale and purified it to high purity (> 4 mg RNA per liter of culture, > 97% homogeneity). Deep sequencing analyses revealed that htRNASer/miR-1291 was selectively processed to target miR-1291-5p to modulate PC cell transcriptome. Proteomics study showed that a number of proteins were reduced remarkably in AsPC-1 cells by biologic miR-1291-5p, among which PNPO, an enzyme that mediates the synthesis of essential nutrient vitamin B6 (VB6), was revealed as a leading target of miR-1291-5p. In addition to PNPO and previously reported SLC2A1/GLUT1, transporter SLC7A5/LAT1 was verified as a direct target for miR-1291-5p. Downregulation of PNPO, LAT1, GLUT1 protein expression by biological miR-1291 led to sharp alteration of homeostasis of glucose, amino acids, and VB6 in human PC cells, and subsequently an increase of oxidative stress. Subsequently, the glycolysis capacity and mitochondrial function of PC cells were significantly suppressed as demonstrated by Seahorse live cell analyses. In addition, combination treatment with htRNASer/miR-1291 and 5-FU exerted synergism in the inhibition of PC cell growth. Overall, our studies revealed a critical role of miR-1291 in the regulation of PC cell metabolism which may provide novel insight in developing new therapeutic strategies for PC.

Bioengineered Mir-328-3p Modulates GLUT1-mediated Glucose Uptake and Metabolism to Exert Synergistic Antiproliferative Effects with Chemotherapeutics

Bioengineered Mir‐328‐3p Modulates SLC2A1/GLUT1‐mediated Glucose Uptake and Metabolism to Exert Synergistic Antiproliferative Effects with Chemotherapeutics

Bioengineered Mir-27B-3p and Mir-328-3p Modulate Drug Metabolism and Disposition Via the Regulation of Target ADME Gene Expression.

Fully‐humanized Bioengineered Mir‐1291 Modulates Key Nutrient Transport and Metabolism to Exert Synergistic Anticancer Effects with Chemotherapeutics

Bioengineered Mir‐34a Targets MPV17L2 to Control Cancer Cell Mitochondrial Functions

Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions

Bioengineered Microrna-1291 Effects on Pancreatic Cancer Cell Proliferation and Xenograft Tumor Growth.

Genetically Engineered Pre-Microrna-34a Prodrug Suppresses Orthotopic Osteosarcoma Xenograft Tumor Growth Via the Induction of Apoptosis and Cell Cycle Arrest

Bioengineered Mir-124-3p Prodrug Selectively Alters the Proteome of Human Carcinoma Cells to Control Multiple Cellular Components and Lung Metastasis in Vivo

Combination Therapy with Bioengineered Mir-34A Prodrug and Doxorubicin Synergistically Suppresses Osteosarcoma Growth.

Mir-150 Up-Regulates Glut1 and Increases Glycolysis in Osteosarcoma Cells

The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug

Single Bioengineered Ncrna Molecule for Dual-Targeting Toward the Control of Non-Small Cell Lung Cancer Patient-Derived Xenograft Tumor Growth.

MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)

Mir-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell Through Targeting the Glutaminase [Gls]-Mediated Glutamine Metabolism.

Mir-522-3p Promotes Osteosarcoma Cell Growth by Regulating Glucose Uptake and GLUT1 Expression

Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting Mir-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells

Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.

Bioengineering Novel Chimeric Microrna-34A for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.

Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy.

Mir-328-5p Inhibits MDA-MB-231 Breast Cancer Cell Proliferation by Targeting RAGE.